Component of a protein kinase signal transduction cascade (PubMed:9808624). Activates the ERK and JNK kinase pathways by phosphorylation of MAP2K1 and MAP2K4 (PubMed:9808624). May phosphorylate the MAPK8/JNK1 kinase (PubMed:17761173).
Activates CHUK and IKBKB, the central protein kinases of the NF-kappa-B pathway (PubMed:9808624)
Binds both upstream activators and downstream substrates in multimolecular complexes through its N-terminus (PubMed:9808624). Oligomerizes after binding MAP2K4 or TRAF2 (PubMed:9808624). Interacts with AXIN1 (PubMed:12223491, PubMed:15262978).
Interacts (via the kinase catalytic domain) with STK38 (PubMed:17906693). Interacts with GRIPAP1 (PubMed:17761173)
A disorder of sex development. Affected individuals have a 46,XY karyotype but present as phenotypically normal females.
Click a pathway to open the interactive Reactome viewer.
Genes with an experimentally identified or computationally predicted synthetic-lethal relationship to MAP3K15, aggregated across our SSL data sources. Click any partner node to view that gene’s page.
Nodes and edges are coloured by the SSL data source. Partners appearing in more than one source are shown in grey.
Total Trials Found: 32
| NCT ID | Condition | Brief Title | Phase | Status |
|---|---|---|---|---|
| NCT03176485 | Metastatic Cancer, Melanoma, Colon Cancer, Differentiated Thyroid Cancer, Hepatocellular Carcinoma, Renal Cell Carcinoma, Metastatic Melanoma, HCC, Metastatic Colon Cancer | Evaluation of Pathway Modulation by Raf, MEK, & Kinase Inhibitors | NA | COMPLETED |
| NCT03416933 | Melanoma (Skin) | Therapeutic Drug Monitoring of BRAF-mutated Advanced Melanoma | NA | COMPLETED |
| NCT06555237 | Cardiomegaly, Noonan Syndrome | MEK Inhibitors for the Treatment of Hypertrophic Cardiomyopathy in Patients With RASopathies | PHASE2 | RECRUITING |